Canadian Pharmacy Blog

Amylin Pharmaceuticals, Inc., has announced the FDA’s approval of pram-lintide acetate (Symlin®) injection to be used in conjunction with insulin to treat type-1 and type-2 diabetes. This product is to be used at mealtime in diabetic patients who have been unable to achieve desired glucose control despite optimal insulin therapy. The self-administered injection causes less [...]

Sitagliptin generic phosphate (Januvia, Merck), the first diabetes treatment approved in a new class of drugs known as DDP-4 inhibitors, enhances the body’s own ability to lower elevated blood glucose levels. The FDA approved the tablets for use in addition to diet and exercise to improve blood sugar levels in patients with type-2 diabetes; the [...]